China Drugmakers Erase $26 Billion as Price Cuts Roil Market
(Bloomberg) -- A meltdown in Chinese pharmaceutical stocks intensified, erasing $26 billion in market value over two days on concerns the government is driving down generic drug prices through a new procurement program.
The MSCI China Health Care Index headed for its biggest two-day drop since 2005. Sino Biopharmaceutical Ltd. is poised for its largest two-day decline ever, after Citigroup said it would be among the worst hit and cut its target price and earnings forecasts.
The severe price cuts have arisen from a new government procurement program that's designed to control medical costs by getting 11 major cities, including Beijing and Shanghai, to combine their purchasing from drug companies. The winner of the tender process for each of the 31 drugs will become the sole supplier for hospitals in all of those cities, but at a much reduced price from before.
Read more: How China's New Drug-Buying Program Is Causing Pain: QuickTake
The plan has been opposed by both domestic and foreign pharmaceuticals from the start because of its impact on prices, but also because reliance on one supplier for each drug could potentially cause quality and supply issues in the future.
Pilot Program
While the government said that this was a pilot program, analysts expect centralized drug procurement to be the new normal for the generics market in China.
“This is just the beginning” said Kay Mai, an analyst at Guotai Junan Securities Co. “We expect the government to expand the catalog of the drug list and include more cities in order to lower the drug costs for citizens. This trend is negative for drugmakers and sales growth of generic drugs in China should slow down in the future.”
Read more: How Beijing Helped Burst the Bubble in Chinese Drugmaker Stocks
Official results from the tender process haven't been announced yet. Calls to China's National Health Commission and Shanghai's drug-procurement website, which had details of the program, went unanswered. Still, estimates that the bidding cut prices by as much as over 90 percent is rattling investors.
Some analysts said the market is over-reacting to the news. Cyrus Ng and Lois Zhou at Jefferies Hong Kong Ltd. said a 90 percent price cut is only for the extreme cases. “As a whole, we expect the overall price cut level to stay in line with previous market expectations of 40 to 50 percent," they wrote in a note.
Successful Tenders
CSPC Pharmaceutical Group Ltd. plummeted as much as 13 percent Friday, on top of a 14 percent drop the previous day. Even companies that said they were among the winners in the tender process fell. Zhejiang Jingxin Pharmaceutical Co., which said its three drugs won bids, dropped as much as 10 percent. The MSCI China Health Care Index dropped as much as 6.8 percent, after falling 8.6 percent on Thursday.
Sino Biopharmaceutical, which successfully bid to provide two drugs to Chinese cities in the program, tumbled as much as 13 percent Friday. Citigroup cut its target price to HK$13.2 from HK$16, and sales and earnings forecasts for the next two years.
Zhejiang Huahai Pharmaceutical Co., which won six of the seven tenders with an average price cut of 45 percent, is the biggest winner for the tender process, according to Jefferies. AstraZeneca Plc and Bristol-Myers Squibb Co. are the only two multi-national companies that won one tender each, slashing prices by 76 percent and 62 percent, respectively, Jefferies said.
AstraZeneca and Bristol-Myers didn't immediately respond to requests for comment. Zhejiang Huahai said the growth opportunities under the government's plan will help outweigh the lower prices.
“The company will be able to expand sales of the products and raise market share,” it said in a statement to the Shanghai stock exchange Thursday night. “This will raise the company's brand profile, and bring about a positive effect for the company's future earnings."
--With assistance from Jeanny Yu and Ryan Lovdahl.
To contact Bloomberg News staff for this story: Daniela Wei in Hong Kong at jwei74@bloomberg.net;Rachel Chang in Shanghai at wchang98@bloomberg.net
To contact the editors responsible for this story: K. Oanh Ha at oha3@bloomberg.net, Jeff Sutherland
©2018 Bloomberg L.P.
With assistance from Editorial Board
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
